ArticleBioactive materials2025
Trapzyme as multimodal Janus nanoplatform for apoptosis-based immunotherapy of periodontitis.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Guanidine-quaternary ammonium polymer-derived carbon dots differentially modulate bacterial respiration and osteoblast mitochondria to resolve infection and foster osteointegration.Bioactive materials · 2027Article
- Mitochondria-targeted nanozyme hydrogel remodels the microenvironment to enhance bone regeneration in diabetes-associated periodontitis.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulation of pro-inflammatory macrophages caused by apoptosis deficiency is a major contributing factor for periodontitis progression. Inducing apoptosis of these macrophages is thus a promising approach for periodontitis management but faces multiple challenges including off-target effects, bacterial infection, redox imbalance and pro-inflammatory stimulus. Herein, we present a multimodal nanoplatform, termed Trapzyme, comprising a gelatin-bilirubin conjugate core and a macrophage membrane shell functionalized with photosensitizer cyanidin 3-O-glucoside-iron coordination and macrophage-targeting ligand phosphoethanolamine-polyethylene glycol-folate. With this design, Trapzyme is found to function as smart "iron trap" for infection control by leveraging bacterial siderophilic behavior. Upon near-infrared (NIR) irradiation, it enhances bacterial eradication via oxidative stress mechanism while inducing mild photothermal stress to trigger lysosome-mediated apoptosis in pro-inflammatory macrophages. Notably, Trapzyme is endowed with potent reactive oxygen species scavenging activity for rapid restoration of extracellular and intracellular redox balance after phototherapy. This NIR-switchable Janus-faced redox activity of Trapzyme synergically contributes to macrophage homeostasis with its neutralization of pro-inflammatory factors. Due to these multifaceted functions, NIR-tunable Trapzyme delivered by microneedles shows favorable efficacy in periodontal remodeling in mice with periodontitis, providing a precise, programmable and effective strategy for apoptosis-based immunotherapy of periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.